×

Industry > Biotechnology firms: Countries Compared

Ian Graham, Staff Editor

Author: Ian Graham, Staff Editor

Cuba is the largest medicine exporter in Latin America, with more than 50 client nations. The main markets for Cuba’s medicines are former Soviet states and third world countries. Cuban medicines are popular because they are cheaper than those produced in developed countries, though some cannot be sold in countries that respect patent laws.

In 1994, Cuba exported $110 million worth of medical supplies. In 1995, this figure rose to $125 million.

Cuban biotechnology researchers have been granted more than 100 patents, include 26 in the United States. In October 1999 SmithKline Beecham, announced details of an agreement to test and market a Cuban meningitis vaccine, first in Europe and eventually in the U.S. Cuban biotechnology research is responsible for drugs such as recombinant streptokinase, a "clot-buster" for heart attack victims produced at a fraction of the cost of similar medicines in developed countries.

DEFINITION: Number of independent dedicated biotechnology firms in major European countries, as of December 2001.

CONTENTS

# COUNTRY AMOUNT DATE GRAPH
1 Germany 504 firms 2001
2 France 342 firms 2001
3 Sweden 235 firms 2001
4 Switzerland 93 firms 2001
5 Netherlands 79 firms 2001
6 Italy 64 firms 2001
7 Belgium 55 firms 2001
8 Finland 53 firms 2001
9 Denmark 51 firms 2001
10 Ireland 39 firms 2001
11 Norway 37 firms 2001
12 Spain 32 firms 2001

Citation

"Countries Compared by Industry > Biotechnology firms. International Statistics at NationMaster.com", Pammolli and Riccaboni, 2001, based on BID, University of Siena. Aggregates compiled by NationMaster. Retrieved from http://www.nationmaster.com/country-info/stats/Industry/Biotechnology-firms

Industry > Biotechnology firms: Countries Compared Map

NationMaster

Interesting observations about Industry > Biotechnology firms

0

Cuba is the largest medicine exporter in Latin America, with more than 50 client nations. The main markets for Cuba’s medicines are former Soviet states and third world countries. Cuban medicines are popular because they are cheaper than those produced in developed countries, though some cannot be sold in countries that respect patent laws.

In 1994, Cuba exported $110 million worth of medical supplies. In 1995, this figure rose to $125 million.

Cuban biotechnology researchers have been granted more than 100 patents, include 26 in the United States. In October 1999 SmithKline Beecham, announced details of an agreement to test and market a Cuban meningitis vaccine, first in Europe and eventually in the U.S. Cuban biotechnology research is responsible for drugs such as recombinant streptokinase, a "clot-buster" for heart attack victims produced at a fraction of the cost of similar medicines in developed countries.

Posted on 20 Mar 2005

Ian Graham, Staff Editor

Ian Graham, Staff Editor

0

It would be nice if this included all the countries in europe. And even better if they included the rest of the world. Isnt england leading in biotech in europe? Strange i dont find england. Hungary should also be included, with 77+- firms.
czech and poland is 40+ too. Germany is probably not nr 1 after being compared with usa, naturally because of its size. I suspect that this wont give a realistic picture of biotechnology firms in europe, nor the world.

Posted on 30 Jun 2010

Halesuhtem

Halesuhtem

Follow us on Facebook to get interesting stats: